Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Associate Professor Sarah De Val is part of a research network that has recently secured funding from The Foundation Leducq Transatlantic Networks of Excellence Programme. 

The programme provides $6,000,000 over five years to teams of researchers working collaboratively in the areas of cardiovascular and neurovascular disease.

The network that Sarah is collaborating with, is researching transcription factor Klf2 and cardiovascular disease and is made up of six PIs from around the world, including a European Coordinator and a North American Coordinator. 

Transcription factors are a wide number of proteins that initiate and regulate the process of converting, or transcribing, DNA (the essential material of genes) into RNA (the copy of DNA used to direct the making-or coding- of all other proteins).

This network will thoroughly study one transcription factor called Kruppel-like factor (Klf) 2. The group notes that Klf2 has a central role in many cardiovascular processes, and works in the lining of arteries, in the lymph system and in the brain’s blood vessels.

The network brings together a group of investigators with expertise in vascular biomechanics, metabolism, gene transcription, mouse genetics and disease models to understand Klf2 regulation and function in these diverse biologic settings. They believe that a strong molecular focus on this single factor is required to make true breakthrough discoveries about human cardiovascular disease.

Congratulations to Sarah and her collaborators! 

Similar stories

Louisa Zolkiewski awarded the Bruce Cattanach Prize 2022

Congratulations are in order for Louisa Zolkiewski, who completed her DPhil studies this year, on being awarded the 2022 Bruce Cattanach Prize by the Genetics Society for her DPhil thesis.

Key cause of type 2 diabetes uncovered

Research led by Dr Elizabeth Haythorne and Professor Frances Ashcroft reveals high blood glucose reprograms the metabolism of pancreatic beta-cells in diabetes. They have discovered that glucose metabolites, rather than glucose itself, are key to the progression of type 2 diabetes. Glucose metabolites damage pancreatic beta-cell function, so they are unable to release enough of the hormone insulin. Reducing the rate at which glucose is metabolised, and these glucose metabolites build up, can prevent the effects of hyperglycaemia.

New study shows clinical symptoms for Alzheimer’s can be predicted in preclinical models

Establishing preclinical models of Alzheimer’s that reflect in-life clinical symptoms of each individual is a critically important goal, yet so far it has not been fully realised. A new collaborative study from the University of Oxford has demonstrated that clinical vulnerability to an abnormally abundant protein in Alzheimer’s brain is in fact reflected in individual patient induced pluripotent stem cell-derived cortical neurons.

Updating the circuit maps of the sympathetic neural network

A new review from Professor Ana Domingos’ lab and colleagues offers a fresh modern viewpoint on sympathetic neurons and their relation to immune cells and obesity.

New Pfizer grant paves the way to a better understanding of how body fat is controlled

Professor Ana Domingos has been awarded a highly competitive independent research grant from Pfizer to discover ‘the role of Sympathetic-associated Perineurial barrier Cells in obesity’.